ClinicalTrials.gg
CompletedNCT03281538Updated Oct 14, 2021Results posted

Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

A Phase 3 interventional study of CR845 in Uremic Pruritus, sponsored by Cara Therapeutics, Inc.. Completed at 27 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-14.

Sponsored by Cara Therapeutics, Inc. (part of Tvardi Therapeutics, Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
288
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 19 studies testing difelikefalin in Pruritus — 2 open to participants now, 2 under way, none of them phase 3. difelikefalin · Pruritus.

Enrollment
4th of 19
288 · median 226
Started
2017
the only one that year
Phase 3
9 of 19
none open now
Registered
3rd of 19
by date
Lead sponsor
14 of 19
Cara Therapeutics, Inc.

Among the 19 studies testing difelikefalin in Pruritus, this one is the 4th largest by enrollment, is the only one that started in 2017, is one of 9 in phase 3, and was the 3rd registered.

Pruritus

491 studies on the registry are indexed under Pruritus; 94 are open to participants now.

Browse Pruritus studies →

Open to participants now

2 of the 19 studies testing difelikefalin in Pruritus are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About difelikefalin

difelikefalin: first FDA approval 2021 (KORSUVA), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 54 Pruritus studies recruiting now, 22 (41%) set no upper age limit and 24 (44%) stop at 75 or younger; 15 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing difelikefalin in Pruritus, or all of them as a file.
02

Study summary

This is an open-label multicenter, long-term extension safety study to evaluate the safety of IV CR845 administered after each dialysis session over a Treatment Period of up to 52 weeks.

Read the detailed description

This is an open-label multicenter, long-term extension safety study to evaluate the safety of IV CR845 administered after each dialysis session over a Treatment Period of up to 52 weeks. This study will consist of a Screening Visit, a 52 week Treatment Period, and a Follow-up Visit. Informed consent will be obtained prior to performing any study-specific procedures. All patients will have a Screening Visit, which can be performed anytime within 14 days prior to the first dose of study drug, to confirm eligibility.

Clinical laboratory tests, electrocardiograms (ECGs), vital signs, adverse events, and concomitant medications will be monitored throughout the study. Blood samples for inflammatory biomarkers will be collected from all patients prior to dialysis on Day 1 and periodically until the End of Treatment or Early Termination Visit. Blood samples will also be collected periodically for clinical laboratory tests.

03

Conditions studied

  • Uremic Pruritus

Keywords

  • CR845
  • difelikefalin
  • Pruritus
  • Chronic Itch
  • Itch
  • Itching
  • hemodialysis
  • Uremic Pruritus
  • Dialysis
  • CKD
  • CKD-associated pruritus
  • CKD-aP
  • ESRD (end stage renal disease)
  • Chronic Kidney Disease
  • Kidney failure, chronic
  • Kidney dysfunction
  • Generalized pruritus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To be eligible for inclusion into the study, a patient must meet the following criteria:

  1. Willing and able to provide written prior to participating in this study;
  2. Able to communicate clearly with the Investigator and staff, able to understand the study procedures, and able and willing to comply with the study schedules and all study requirements;
  3. Males or females 18 years of age or older;
  4. Currently on hemodialysis for end-stage renal disease and has been categorized as experiencing moderate to severe uremic pruritus;
  5. If female:

    1. Is not of (surgically sterile or , as defined in Section 6.5.1.6); or
    2. Has a negative serum pregnancy test at screening and agrees to use acceptable measures (as defined in Section 6.5.1.6) from the time of informed consent until the safety Follow-up Visit or 7 days after the last dose of study drug, whichever is later.
  6. If male, agrees not to donate sperm after the first dose of study drug until 7 days after the last dose, and agrees to use a condom with spermicide or abstain from heterosexual intercourse during the study until 7 days after study drug administration. (Note: No restrictions are required for a vasectomized male provided his vasectomy was performed ≥4 months prior to dosing);
  7. Has a dry body weight of ≥40.0 kg at screening (prescription target dry body weight);
  8. Has adequacy of dialysis, defined as meeting 1 of the following criteria during the 3 months prior to screening:

    1. ≥2 single pool Kt/V measurements ≥1.2; or
    2. ≥2 urea reduction ratio measurements ≥65%; or
    3. 1 single pool Kt/V measurement ≥1.2 and 1 urea reduction ratio measurement ≥65%

Exclusion criteria

Exclusion Criteria:

A patient will be excluded from the study if any of the following criteria are met:

  1. Received an drugwithin 30 days prior to the first dose of study drug, or is planning to participate in another interventional clinical study while enrolled in this study.
  2. Has a concomitant disease or any medical condition that, in the opinion of the Investigator, could pose undue risk to the patient, impede completion of the study procedures, or would compromise the validity of the study measurements, including, but not limited to:

    1. Known or suspected history of , Fifth Edition, -diagnosed alcohol, narcotic or other drug abuse, or substance dependence within 12 months prior to screening;
    2. Class IV congestive heart failure (Appendix 1, Section 14.0);
    3. Severe mental illness or cognitive impairment (eg, dementia);
    4. Any other relevant acute or chronic medical or neuropsychiatric condition;
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
288 participants (actual)

Study arms

  • Experimental
    CR845 0.5mcg/kg

    CR845 0.5mcg/kg IV medication administered three times/week after dialysis

    Drug: CR845

Interventions

  • DrugCR845

    IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)

06

What researchers measure

Primary outcomes

  1. Number of Participants With AEs

    Assessed by physical examination, monitoring of adverse events, vital signs and laboratory assessments

    Time frame: Up to 52 weeks

07

Results

Posted Oct 14, 2021

Participant flow

Participant flow — Overall Study
MilestoneCR845 0.5mcg/kg
Started288
Completed133
Not completed155

Outcome measures

PrimaryNumber of Participants With AEs

Assessed by physical examination, monitoring of adverse events, vital signs and laboratory assessments

Time frame:
Up to 52 weeks
Reported as:
Count of participants · Participants
Number of Participants With AEs
ParticipantsCR845 0.5mcg/kg
Number of Participants With AEs240

Adverse events

Collected over Up to 52 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CR845 0.5mcg/kg17/288 (5.9%)148/288 (51.4%)139/288 (48.3%)
Most frequent serious events
Showing 10 of 189
Most frequent serious events
EventCR845 0.5mcg/kg
Fluid overloadMetabolism and nutrition disorders17/288
HyperkalaemiaMetabolism and nutrition disorders15/288
Acute myocardial infarctionCardiac disorders14/288
PneumoniaInfections and infestations12/288
SepsisInfections and infestations9/288
HypotensionVascular disorders9/288
Angina pectorisCardiac disorders8/288
Cardiac arrestCardiac disorders8/288
Cardiac failure congestiveCardiac disorders8/288
Non-cardiac chest painGeneral disorders8/288
Most frequent other events
Most frequent other events
EventCR845 0.5mcg/kg
NauseaGastrointestinal disorders48/288
DiarrhoeaGastrointestinal disorders44/288
FallInjury, poisoning and procedural complications42/288
VomitingGastrointestinal disorders38/288
HypotensionVascular disorders30/288
Non-cardiac chest painGeneral disorders22/288
DizzinessNervous system disorders21/288
Abdominal painGastrointestinal disorders18/288
Pain in extremityMusculoskeletal and connective tissue disorders16/288
ArthralgiaMusculoskeletal and connective tissue disorders15/288

Baseline characteristics

Age, Continuous
Age, Continuous(years)CR845 0.5mcg/kg
Mean57.4 ± 12.61
Sex: Female, Male
Sex: Female, Male(Participants)CR845 0.5mcg/kg
Female115
Male173
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CR845 0.5mcg/kg
American Indian or Alaska Native12
Asian9
Native Hawaiian or Other Pacific Islander2
Black or African American148
White114
More than one race1
Unknown or Not Reported2
08

Study locations

27 sites
  • Cara Therapeutics Study Site
    Chula Vista, California 91990, United States
  • Cara Therapeutics Study Site
    El Centro, California 92243, United States
  • Cara Therapeutics Study Site
    Long Beach, California 90813, United States
  • Cara Therapeutics Study Site
    Northridge, California 91324, United States
  • Cara Therapeutics Study Site
    Denver, Colorado 80230, United States
  • Cara Therapeutics Study Site
    Hollywood, Florida 33024, United States
  • Cara Therapeutics Study Site
    Tampa, Florida 33614, United States
  • Cara Therapeutics Study Site
    Winter Park, Florida 32789, United States
  • Cara Therapeutics Study Site
    Albany, Georgia 31701, United States
  • Cara Therapeutics Study Site
    Augusta, Georgia 30909, United States
  • Cara Therapeutics Study Site
    Meridian, Idaho 83642, United States
  • Cara Therapeutics Study Site
    Springfield, Massachusetts 01107, United States
  • Cara Therapeutics Study Site
    Roseville, Michigan 48066, United States
  • Cara Therapeutics Study Site
    Kansas City, Missouri 64131, United States
  • Cara Therapeutics Study Site
    Albuquerque, New Mexico 87109, United States
  • Cara Therapeutics Study Site
    Gallup, New Mexico 87301, United States
  • Cara Therapeutics Study Site
    Mineola, New York 11501, United States
  • Cara Therapeutics Study Site
    Ridgewood, New York 11385, United States
  • Cara Therapeutics Study Site
    Bethlehem, Pennsylvania 18017, United States
  • Cara Therapeutics Study Site
    Knoxville, Tennessee 37920, United States
  • Cara Therapeutics Study Site
    El Paso, Texas 79902, United States
  • Cara Therapeutics Study Site
    San Antonio, Texas 78202, United States
  • Cara Therapeutics Study Site
    San Antonio, Texas 78221, United States
  • Cara Therapeutics Study Site
    San Antonio, Texas 78229, United States
  • Cara Therapeutics Study Site
    Saint George, Utah 84790, United States
  • Cara Therapeutics Study Site
    Wauwatosa, Wisconsin 53326, United States
  • Cara Therapeutics Study Site
    San Juan, 00926, Puerto Rico
09

References and documents

Publications

  • Fishbane S, Wen W, Munera C, Lin R, Bagal S, McCafferty K, Menzaghi F, Goncalves J. Safety and Tolerability of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis From the Phase 3 Clinical Trial Program. Kidney Med. 2022 Jun 28;4(8):100513. doi: 10.1016/j.xkme.2022.100513. eCollection 2022 Aug. PubMed 36039153 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in Feb 2020, 29 months.

Results were first posted in Oct 2021, 1 year 8 months after primary completion. A results delay was requested in Feb 2021.

Of 42 industry-sponsored phase 3 interventional studies under Pruritus, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 26. This study's 29 months is above that.

Counting every sponsor, half of 48 studies reached it within 19 months; a quarter within 12 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2017
First posted
Sep 13, 2017
StartActual
Aug 14, 2017
Primary completionActual
Feb 11, 2020
CompletionActual
Feb 11, 2020
Results delay requested
Feb 10, 2021
Results first posted
Oct 14, 2021
Last update
Oct 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03281538
Responsible party
Sponsor
First posted
Sep 13, 2017
Start date
Aug 14, 2017
Primary completion
Feb 11, 2020
Completion
Feb 11, 2020
Results posted
Oct 14, 2021
Last update
Oct 14, 2021

Study contacts

Frederique Menzaghi
study director · Cara Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Difelikefalin

Start the discussion